1.Acton, J. P. Evaluating public programs to save lives: The case of heart attacks. Santa Monica, CA: RAND report R-950-RC, 1973.
2.Amery, A., Brixko, P., Clement, D., et al. Mortality and morbidity results from the European working party on high blood pressure in the elderly trial. Lancet, 1985, ii, 1349–54.
3.Bishop, R. C., & Heberlein, J. A.Measuring values of extra market goods: Are indirect measures biased? American Journal of Agricultural Economics, 1979, 61, 926–30.
4.Bowker, J. M., & Stoll, J. R.Use of dichotomous choice nonmarket methods to value the whooping crane resource. American Journal of Agricultural Economics, 1988, 70, 372–81.
5.Boyle, K. J., & Bishop, R. C.Welfare measurements using contingent valuation: A comparison of techniques. American Journal of Agricultural Economics, 1988, 70, 21–28.
6.British Hypertension Society Working Party. Treating mild hypertension. British Medical Journal, 1988, 298, 694–98.
7.Brookshire, D. S., Randall, A., & Stoll, J. R.Valuing increments and decrements of natural resource service flows. American Journal of Agricultural Economics, 1980, 62, 478–88.
8.Brookshire, D. S., Thayer, M. A., Schulze, W. P., & d'Arge, R. C.Valuing public goods: Comparison of survey and hedonic approaches. American Economic Review, 1982, 72, 165–77.
9.Cameron, T. A.A new paradigm for valuing non-market goods using referendum data: Maximum likelihood estimation by censored logistic regression. Journal of Environmental Economics and Management, 1988, 13, 255–68.
10.Cantor, J. C., Morisky, D. E., Green, L. W., et al. Cost-effectiveness of educational interventions to improve patient outcomes in blood pressure control. Preventive Medicine, 1985, 14, 782–800.
11.Carson, R. T. Constructed markets. In Braden, J. B. & Kolstad, C. D. (eds.), Measuring the demand for environmental quality. Amsterdam: Elsevier/North Holland, 1991.
12.Collins, R., Peto, R., MacMahon, S., et al. Blood pressure, stroke, and coronary heart disease, part 2, short term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet, 1990, 335, 827–38.
13.Cummings, R. G., Brookshire, D. S., & Schulze, W. D.Valuing environmental goods. New Jersey: Rowman and Allanheld, 1986.
14.Edelson, J. T., Weinstein, M. C., Tosteson, A. N., et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. Journal of the American Medical Association, 1990, 263, 407–13.
15.Edgar, M. A., & Schnieden, H.The economics of mild hypertension programmes. Social Science and Medicine, 1989, 28, 211–22.
16.Erfurt, J. C., & Foote, A.Cost-effectiveness of work-site blood pressure control programs. Journal of Occupational Medicine, 1984, 26, 892–900.
17.Gegax, D., Gerking, S., & Schulze, W. Perceived risk and the marginal value of safety. Working paper prepared for the U.S. Environmental Protection Agency, 1985.
18.Hammack, B., & Brown, G. M., Jr. Waterfowl and wetlands: Toward bioeconomic analysis. Baltimore, MD: Johns Hopkins University Press for Resources for the Future, 1974.
19.Hanemann, M. W.Welfare evaluations in contingent valuation experiments with discrete responses. American Journal of Agricultural Economics, 1984, 66, 332–41.
20.Helgeland, A.Treatment of mild hypertension: A five-year controlled drug trial, the Oslo study. American Journal of Medicine, 1980, 69, 725–32.
21.Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program, I, reduction in mortality of persons with high blood pressure, including mild hypertension. Journal of the American Medical Association, 1979, 242, 2562–71.
22.Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program, II, mortality by race, sex and age. Journal of the American Medical Association, 1979, 242, 2572–77.
23.Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program, III, reduction in stroke incidence among persons with high blood pressure. Journal of the American Medical Association, 1982, 247, 633–38.
24.Hypertension Detection and Follow-up Program Cooperative Group. The effect of treatment on mortality in “mild” hypertension: Results of the hypertension detection and follow-up program. New England Journal of Medicine, 1982, 307, 976–80.
25.Hypertension Detection and Follow-up Program Cooperative Group. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris, 5-year findings of the hypertension detection and follow-up program. Hypertension, 1984, 6(suppl. I), 198–206.
26.Johannesson, M.Economic evaluation of hypertension treatment. Linköping University, Sweden: Linköping Studies in Arts and Science Nr 67, 1991.
27.Johannesson, M.Buchanan's opportunity cost concept, the contingent valuation method and cost-benefit analysis. Journal des Economistes et des Etudes Humaines, 1991, 2, 123–33.
28.Johannesson, M.A note on the discounting of gained life-years in cost-effectiveness analysis. International Journal of Technology Assessment in Health Care, 1992, 8, 359–68.
29.Johannesson, M., Åberg, H., Agréus, L., et al. Cost-benefit analysis of non-pharmacological treatment of hypertension. Journal of Internal Medicine, 1991, 230, 307–12.
30.Johannesson, M., Borgquist, L., & Jönsson, B.The costs of treating hypertension in Sweden: An empirical investigation in primary health care. Scandinavian Journal of Primary Health Care, 1991, 9, 155–60.
31.Johannesson, M., Borgquist, L., Jönsson, B., & Råstam, L.The costs of treating hypertension: An analysis of different cut-off points. Health Policy, 1991, 18, 141–50.
32.Johannesson, M., Hedbrant, J., & Jönsson, B.A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Medical Informatics, 1991, 16, 355–62.
33.Johannesson, M., & Jönsson, B. Cost-effectiveness analysis of hypertension treatment: Methodological issues. Linköping University, Sweden: Center for Medical Technology Assessment, CMT report, 1990.
34.Johannesson, M., & Jönsson, B.Cost-effectiveness analysis of hypertension treatment: A review of methodological issues. Health Policy, 1991, 19, 55–78.
35.Johannesson, M., & Jönsson, B.Economic evaluation in health care: Is there a role for cost-benefit analysis? Health Policy, 1991, 17, 1–23.
36.Johannesson, M., Jönsson, B., & Borgquist, L.Willingness to pay for antihypertensive therapy: Results of a Swedish pilot study. Journal of Health Economics, 1991, 10, 461–74.
37.Johansson, P.-O.The economic theory and measurement of environmental benefits. Cambridge, U.K.: Cambridge University Press, 1987.
38.Jones-Lee, M. W.The value of life: An economic analysis. London: Martin Robertson, 1976.
39.Jones-Lee, M. W., Hammerton, M., & Philips, P. R.The value of safety: Results of a national sample survey. Economic Journal, 1985, 95, 49–72.
40.Jönsson, B.Ekonomiska konsekvenser av de nya behandlingsriktlinjerna mot hypertoni. In Berglund, G. (ed.), Hypertoni 87, Mölndal: Hässle Läkemedel AB, 1988.
41. Jönsson, B. Applications of cost-benefit analysis to health problems. In Halberstadt, V. & Culyer, A. J. (eds.), Public economics and human resources. Proceedings of the 31st congress of the International Institute of Public Finance. Editions Cujas, 1977.
42.Jönsson, B.Cost-benefit analysis in public health and medical care. Lund: Liber, 1976.
43.Jönsson, B., Horisberger, B., Bruguera, M., & Matter, L.Cost-benefit analysis of hepatitis-B vaccination: A computerized model for Spain. International Journal of Technology Assessment in Health Care, 1991, 7, 379–402.
44.Kannel, W. B., Wolf, P. A., & Garrison, R. J. (eds.). The Framingham study: An epidemio-logical investigation of cardiovascular disease, section 34, some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements, 30-year follow-up. Springfield, IL: U.S. Department of Commerce, National Technical Information Service, 1987.
45.Kannel, W. B., Wolf, P. A., & Garrison, R. J. (eds.). The Framingham study: An epidemio-logical investigation of cardiovascular disease, section 37, the probability of developing certain cardiovascular diseases in eight years at specified values of some characteristics. Springfield, IL: U.S. Department of Commerce, National Technical Information Service, 1987.
46.Kawachi, I., & Malcolm, L. A.The cost-effectiveness of treating mild-to-moderate hypertension: A reappraisal. Journal of Hypertension, 1991, 9, 199–208.
47.Keeler, E. B., & Cretin, S.Discounting of life-saving and other nonmonetary effects. Management Science, 1983, 29, 300–06.
48.Keys, A.Seven countries. Cambridge, MA: Harvard University Press, 1980.
49.Knetsch, J. L., & Sinden, J. A.Willingness to pay and compensation demanded: Experimental evidence of an unexpected disparity in measures of value. Quarterly Journal of Economics, 1984, 98, 507–21.
50.Kriström, B. Valuing environmental benefits using the contingent valuation method: An econometric analysis. Ph.D. dissertation. University of Umeå: Umeå Economic Studies No. 219, 1990.
51. Kriström, B. Discrete and continuous valuation questions; Do they give different answers? Swedish University of Agricultural Sciences in Umeå: Department of Forest Economics, Working paper 90, 1989.
52.Kriström, B.A nonparametric approach to the estimation of welfare measures in discrete response valuation studies. Land Economics, 1990, 66, 135–39.
53.Laaser, U., & Wenzel, H.Antihypertensive treatment in Germany, subjected to a cost-effectiveness analysis. Journal of Human Hypertension, 1990, 4, 436–40.
54.Lindgren, B., & Persson, U.The cost-effectiveness of a new antihypertensive drug, dox-azosin. Current Therapeutic Research, 1989, 45, 738–60.
55.Littenberg, B., Garber, A. M., & Sox, H. C.Screening for hypertension. Annals of Internal Medicine, 1990, 112, 192–202.
56.Logan, A. G., Milne, B. J., Achber, C., et al. Cost-effectiveness of a worksite hypertension treatment programme. Hypertension, 1981, 3, 211–18.
57.Läkemedelsstatistik, AB.Swedish drug market (SDM) 89:3. Stockholm: Läkemedelsstatistik AB, 1989.
58.MacMahon, S., Peto, R., Cutler, J., et al. Blood pressure, stroke, and coronary heart disease, part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet, 1990, 335, 765–74.
59.Medical Research Working Party. MRC trial of treatment of mild hypertension: Principal results. British Medical Journal, 1985, 291, 97–104.
60.Mishan, E. J.Evaluation of life and limb: A theoretical approach. Journal of Political Economy, 1971, 79, 687–705.
61.Mitchell, R. C., & Carson, R. T.Using surveys to value public goods. Washington, DC: Resources for the Future, 1989.
62.Mitchell, R. C., & Carson, R. T. An experiment in determining willingness to pay for national water quality improvements. Draft report prepared for the U.S. Environmental Protection Agency. Washington, DC: U. S., Environmental Protection Agency, 1981.
63.Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial, risk factor changes and mortality results. Journal of the American Medical Association, 1982, 248, 1465–67.
64.National Board of Health and Welfare Drug Information Committee. Treatment of mild hypertension. Uppsala: National Board of Health and Welfare, 1987.
65.Nissinen, A., Tuomilehto, J., Kottke, T. E., & Puska, P.Cost-effectiveness of the North Karelia hypertension program 1972–1977. Medical Care, 1986, 24, 767–80.
66.OECD. Financing and delivering health care, a comparative analysis of OECD countries. Paris: OECD, 1987.
67.Randall, A., Grunewald, O., Pagoulatos, A., et al. Reclaiming coal surface mines in central Appalachia: A case study of the benefits and costs. Land Economics, 1978, 54, 472–89.
68.Randall, A., Ives, B. C., & Eastman, C.Bidding games for valuation of aesthetic environmental improvements. Journal of Environmental Economics and Management, 1974, 1, 132–49.
69.Råstam, L., Berglund, G., Isacsson, S-O., & Ryden, L.The Skaraborg hypertension project. Acta Medica Scandinavica, 1986, 219, 243–69.
70.Report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet, 1980, 1261–67.
71.Rowe, R. D., d'Arge, R. C., & Brookshire, D. S.An experiment on the economic value of visibility. Journal of Environmental Economics and Management, 1980, 7, 1–19.
72.Russel, L.Is prevention better than cure? Washington, DC: Brookings Institution, 1986.
73.Schelling, T. C. The life you save may be your own. In Chase, S. B. (ed.), Problems in public expenditure analysis. Washington, DC: The Brookings Institution, 1968.
74.Smith, V. K. & Desvousges, W. H.Measuring water quality benefits. Boston, MA: Kluwer-Nijhoff Publishing, 1986.
75.Smith, V. K., & Desvousges, W. H.An empirical analysis of the economic value of risk changes. Journal of Political Economy, 1987, 95, 89–115.
76.Statistiska centralbyrån. Statistical abstract of Sweden 1990. Stockholm: Statistics Sweden, 1989.
77.Stevens, R. D., Bingley, L. J. JrBoger, M., et al. Variability in the management of hypertension and cost-effectiveness: Methodology, community care results and potential cost reductions. Social Science and Medicine, 1984, 18, 767–74.
78.Thompson, M. S.Willingness to pay and accept risks to cure chronic disease. American Journal of Public Health, 1986, 76, 392–96.
79.Tibblin, G., & Åberg, H.Non-pharmacological treatment of hypertension in two steps: 1 year report from eight health centres. Acta Medica Scandinavica, 1987, (suppl. 714), 105–12.
80.Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. Journal of the American Medical Association, 1967, 202, 1028–34.
81.Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension, II, results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. Journal of the American Medical Association, 1970, 213, 1143–52.
82.Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension, III, influence of age, diastolic blood pressure, and prior cardiovascular disease; further analysis of side effects. Circulation, 1972, 45, 991–1004.
83.Waaler, H., Helgeland, A., Hjort, P., et al. Hoyt blodtrykk: Behandlingsprogram, utbytte, kostnader. Oslo: Norges allmenvitenskapelige forskningsråds gruppe for helsetjenste-forskning, Rapport Nr 5, 1978.
84.Weinstein, M. C.Principles of cost-effective resource allocation in health care organizations. International Journal of Technology Assessment in Health Care, 1990, 6, 93–103.
85.Weinstein, M. C., & Stason, W. B.Hypertension: A policy perspective. Cambridge, MA: Harvard University Press, 1976.
86.Weinstein, M. C., & Stason, W. B.Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine, 1977, 296, 732–39.
87.Williams, A., & Sugden, R.The principles of practical cost-benefit analysis. Oxford: Oxford University Press, 1978.
88.Åberg, H., & Tibblin, G.Addition of non-pharmacological methods of treatment in patients on antihypertensive drugs: Results of previous medication, laboratory tests and life quality. Journal of Internal Medicine, 1989, 226, 39–46.